NewLink Genetics Announces European Commission Approval for Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®) Nasdaq: NLNK

AMES, Iowa, November 12, 2019 (GLOBE NEWSWIRE) – NewLink Genetics Corporation (NASDAQ: NLNK) was announced on Monday, 11 Novemberth, the European Commission (EC) t conditional marketing authorization for ERVEBO®, Ebola…